Abstract: A composition including anatabine or a salt thereof is provided for treating a nuclear factor erythroid 2-related factor 2 (NRF2)-regulated disorder.) A composition including anatabine or a salt thereof is also provided for prophylactic treatment of a subject requiring NRF2 activation.

Abstract: Systems and methods for assessing a subject's sample to predict the subject's biological status, such as a smoker status. The computer-implemented method includes receiving, by a computer system including at least one hardware processor, a data set associated with the sample. The data set comprises quantitative expression data for a set of genes less than a whole genome, the set of genes comprising AHHR, CDKN1C, LRRN3, PID1, GPR15, SASH1, CLEC10A, LINC00599, P2RY6, DSC2, F2R, SEMA6B, and TLR5. The at least one hardware processor generates a score based on the quantitative expression data for the set of genes in the received data set, wherein the score is based on fewer than 40 genes and is indicative of a predicted smoking status of the subject.

Abstract: The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided. These methods, compositions and molecules can be useful to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Zdhhc2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Zdhhc2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Zdhhc2 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided. These methods, compositions and molecules can be useful to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Zdhhc2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Zdhhc2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Zdhhc2 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Sipa1l1, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Sipa1l1 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Sipa1l1 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Sipa1l1, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Sipa1l1 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Sipa1l1 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Zdhhc2, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Zdhhc2 activity in adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Zdhhc2 activity as well as screening test for identification of modulators of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Vgll3 a new target involved in adipogenesis modulation. Further, the present invention relates to methods to increase Vgll3 activity in adipocytes and preadipocytes. In addition, pharmaceutical composition comprising Vgll3 activity enhancing molecules in order to enhance the Vgll3 activity in a target tissue are also provided. These methods, compositions and molecules can be useful to modulate adipogenesis and thus treat obesity and related disorders.

Abstract: The present invention concerns Plac8, a new target involved in adipogenesis modulation. Using a siRNA approach, the inventors demonstrated that decrease in Plac8 activity in preadipocytes and adipose tissue induces a decrease in adipogenesis. Thus, the present invention relates to modulators of Plac8 activity as well screening test for identification of modulators as of the activity of this target, and their use, especially in pharmaceutical composition, to modulate adipogenesis and thus treat obesity and related disorders.